Table 3.
Summary of univariate analysis and multivariate analysis for overall survival in 247 cases of NSCLC patients
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Average survival time (SE) | 95%CI | P | Exp (B) | 95.0% CI | P | |
| G3BP1 | ||||||
| High expression | 49.84 (3.57) | 42.85‐56.83 | .007* | 0.607 | 0.378‐0.975 | .039* |
| Low expression | 69.68 (5.20) | 59.49‐79.89 | ||||
| YB1 | ||||||
| High expression | 51.32 (3.72) | 44.03‐58.62 | .025* | 0.882 | 0.556‐1.399 | .594 |
| Low expression | 66.77 (5.05) | 56.83‐76.68 | ||||
| p‐AKT | ||||||
| Positive expression | 53.09 (4.42) | 44.44‐61.75 | .037* | 0.694 | 0.447‐1.077 | .103 |
| Negative expression | 60.13 (4.02) | 52.25‐68.00 | ||||
| Clinical stages | ||||||
| Stage I | 80.78 (5.35) | 70.30‐91.27 | .000* | 0.486 | 0.248‐0.956 | .036* |
| Stage II and III | 48.21 (3.13) | 42.09‐54.33 | ||||
| LNM status | ||||||
| LNM | 48.91 (3.81) | 41.44‐56.37 | .001* | 1.457 | 0.862‐2.463 | .160 |
| No LNM | 69.36 (4.82) | 59.91‐78.81 | ||||
| Pathological degree | ||||||
| Well/moderated | 64.85 (4.11) | 56.79‐72.92 | .002* | 0.493 | 0.316‐0.770 | .002* |
| Poor | 51.87 (4.29) | 43.46‐60.27 | ||||
| Histological type | ||||||
| ADC | 51.80 (3.48) | 44.97‐58.62 | .416 | 1.510 | 0.945‐2.413 | .085 |
| SCC | 65.86 (4.84) | 56.37‐75.34 | ||||
| Gender | ||||||
| Female | 60.49 (4.94) | 50.81‐70.17 | .218 | 0.698 | 0.415‐1.173 | .175 |
| Male | 56.94 (3.95) | 49.20‐64.67 | ||||
| Age | ||||||
| <56 | 60.82 (4.48) | 52.05‐69.59 | .851 | 0.900 | 0.587‐1.381 | .631 |
| ≥56 | 54.29 (3.59) | 47.26‐61.33 | ||||
Abbreviations: ADC, adenocarcinoma; CI, confidence interval; Exp(β), odds ratio; LNM, lymph node metastasis; SCC, squamous cell carcinoma; SE, standard error.
*
P < .05.